Migraine - Pipeline Review, H2 2016

Date: November 23, 2016
Pages: 221
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ME908B37F02EN
Leaflet:

Download PDF Leaflet

Migraine - Pipeline Review, H2 2016
Migraine - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine – Pipeline Review, H2 2016, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 12, 14, 14, 20, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.Migraine.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Migraine Overview
Therapeutics Development
Pipeline Products for Migraine - Overview
Pipeline Products for Migraine - Comparative Analysis
Migraine - Therapeutics under Development by Companies
Migraine - Therapeutics under Investigation by Universities/Institutes
Migraine - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Migraine - Products under Development by Companies
Migraine - Products under Investigation by Universities/Institutes
Migraine - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Acorda Therapeutics Inc
Afferent Pharmaceuticals Inc
Alder Biopharmaceuticals Inc
Allergan Plc
Amgen Inc
Aralez Pharmaceuticals Inc
Astellas Pharma Inc
Biofrontera AG
BioHealthonomics Inc
Bristol-Myers Squibb Company
Charleston Laboratories Inc
CoLucid Pharmaceuticals Inc
Corium International Inc
Eli Lilly and Company
Impel NeuroPharma Inc
InStar Technologies AS
Klaria Pharma Holding AB
Medestea Research & Production SpA
Merck & Co Inc
Mithra Pharmaceuticals SA
Monosol Rx LLC
NAL Pharmaceuticals Ltd
Noxxon Pharma AG
Otsuka Holdings Co Ltd
Promius Pharma LLC
RedHill Biopharma Ltd
Revance Therapeutics Inc
Shin Nippon Biomedical Laboratories Ltd
Strategic Science & Technologies LLC
Suda Ltd
Teva Pharmaceutical Industries Ltd
TheraJect Inc
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Trigemina Inc
TrioxBio Inc
Vertex Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
Zosano Pharma Corp
Migraine - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dextromethorphan + quinidine sulfate) - Drug Profile
(naproxen sodium + sumatriptan succinate) - Drug Profile
(promethazine [INN] + sumatriptan succinate) - Drug Profile
AA-71 - Drug Profile
AF-130 - Drug Profile
AGN-241689 - Drug Profile
ALD-1910 - Drug Profile
ALD-403 - Drug Profile
AMG-301 - Drug Profile
AST-003 - Drug Profile
Atogepant - Drug Profile
BF-1 - Drug Profile
C-012 - Drug Profile
cloxyquin - Drug Profile
Deina - Drug Profile
dexisometheptene - Drug Profile
DFN-02 - Drug Profile
DFN-10 - Drug Profile
DFN-14 - Drug Profile
DFN-15 - Drug Profile
DFN-19 - Drug Profile
DFN-42 - Drug Profile
dihydroergotamine mesylate - Drug Profile
dihydroergotamine mesylate - Drug Profile
DIS-COM-TROP - Drug Profile
DORA-12 - Drug Profile
Drug 1 for Migraine and Cancer Pain - Drug Profile
Drug 2 for Migraine and Cancer Pain - Drug Profile
Drug 3 for Migraine and Cancer Pain - Drug Profile
Drug for Migraine - Drug Profile
Drug for Migraine and Cancer Pain - Drug Profile
erenumab - Drug Profile
Estetrol - Drug Profile
flunarizine hydrochloride - Drug Profile
galcanezumab - Drug Profile
histamine dihydrochloride - Drug Profile
ketoprofen - Drug Profile
KL-00204 - Drug Profile
lasmiditan succinate - Drug Profile
MK-8031 - Drug Profile
MTR-106 - Drug Profile
Nociceptin - Drug Profile
NOXL-41 - Drug Profile
NXN-188 - Drug Profile
NXN-462 - Drug Profile
oxytocin - Drug Profile
picotamide - Drug Profile
propofol hemisuccinate - Drug Profile
Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile
rizatriptan benzoate - Drug Profile
rizatriptan benzoate - Drug Profile
rizatriptan benzoate - Drug Profile
RT-001 - Drug Profile
Small Molecule to Antagonize CALCRL for Migraine - Drug Profile
Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile
Small Molecule to Antagonize Kappa Opioid Receptor for Migraine - Drug Profile
Small Molecule to Inhibit CGRP for Migraine - Drug Profile
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Small Molecule to Inhibit nNOS and NET for Migraine and Neuropathic Pain - Drug Profile
Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile
Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine - Drug Profile
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
SST-8055 - Drug Profile
sumatriptan succinate - Drug Profile
sumatriptan succinate - Drug Profile
sumatriptan succinate - Drug Profile
sumatriptan succinate - Drug Profile
TEV-48125 - Drug Profile
Tribarcina - Drug Profile
TRV-250 - Drug Profile
ubrogepant - Drug Profile
zolmitriptan - Drug Profile
zolmitriptan - Drug Profile
zolmitriptan - Drug Profile
zolmitriptan - Drug Profile
Migraine - Dormant Projects
Migraine - Discontinued Products
Migraine - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 216

LIST OF TABLES

Number of Products under Development for Migraine, H2 2016
Number of Products under Development for Migraine - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Migraine - Pipeline by Achelios Therapeutics Inc, H2 2016
Migraine - Pipeline by Acorda Therapeutics Inc, H2 2016
Migraine - Pipeline by Afferent Pharmaceuticals Inc, H2 2016
Migraine - Pipeline by Alder Biopharmaceuticals Inc, H2 2016
Migraine - Pipeline by Allergan Plc, H2 2016
Migraine - Pipeline by Amgen Inc, H2 2016
Migraine - Pipeline by Aralez Pharmaceuticals Inc, H2 2016
Migraine - Pipeline by Astellas Pharma Inc, H2 2016
Migraine - Pipeline by Biofrontera AG, H2 2016
Migraine - Pipeline by BioHealthonomics Inc, H2 2016
Migraine - Pipeline by Bristol-Myers Squibb Company, H2 2016
Migraine - Pipeline by Charleston Laboratories Inc, H2 2016
Migraine - Pipeline by CoLucid Pharmaceuticals Inc, H2 2016
Migraine - Pipeline by Corium International Inc, H2 2016
Migraine - Pipeline by Eli Lilly and Company, H2 2016
Migraine - Pipeline by Impel NeuroPharma Inc, H2 2016
Migraine - Pipeline by InStar Technologies AS, H2 2016
Migraine - Pipeline by Klaria Pharma Holding AB, H2 2016
Migraine - Pipeline by Medestea Research & Production SpA, H2 2016
Migraine - Pipeline by Merck & Co Inc, H2 2016
Migraine - Pipeline by Mithra Pharmaceuticals SA, H2 2016
Migraine - Pipeline by Monosol Rx LLC, H2 2016
Migraine - Pipeline by NAL Pharmaceuticals Ltd, H2 2016
Migraine - Pipeline by Noxxon Pharma AG, H2 2016
Migraine - Pipeline by Otsuka Holdings Co Ltd, H2 2016
Migraine - Pipeline by Promius Pharma LLC, H2 2016
Migraine - Pipeline by RedHill Biopharma Ltd, H2 2016
Migraine - Pipeline by Revance Therapeutics Inc, H2 2016
Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2016
Migraine - Pipeline by Strategic Science & Technologies LLC, H2 2016
Migraine - Pipeline by Suda Ltd, H2 2016
Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
Migraine - Pipeline by TheraJect Inc, H2 2016
Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2016
Migraine - Pipeline by Trevena Inc, H2 2016
Migraine - Pipeline by Trigemina Inc, H2 2016
Migraine - Pipeline by TrioxBio Inc, H2 2016
Migraine - Pipeline by Vertex Pharmaceuticals Inc, H2 2016
Migraine - Pipeline by Xenon Pharmaceuticals Inc, H2 2016
Migraine - Pipeline by Zosano Pharma Corp, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Migraine - Dormant Projects, H2 2016
Migraine - Dormant Projects (Contd..1), H2 2016
Migraine - Dormant Projects (Contd..2), H2 2016
Migraine - Dormant Projects (Contd..3), H2 2016
Migraine - Dormant Projects (Contd..4), H2 2016
Migraine - Dormant Projects (Contd..5), H2 2016
Migraine - Dormant Projects (Contd..6), H2 2016
Migraine - Discontinued Products, H2 2016 204

LIST OF FIGURES

Number of Products under Development for Migraine, H2 2016
Number of Products under Development for Migraine - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


NeurAxon, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Sep, 2014 · 23 pages

Ask Your Question

Migraine - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: